Clinical trials
Lymphoma, B-Cell clinical trials
Below are recruiting lymphoma, b-cell clinical trials, each written for real people, not researchers. We’re tracking 534 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT05800977RecruitingPhase 1/Phase 2
Study of a CAR-T cell treatment for lymphoma that returned
This trial tests a personalized immune-cell treatment (CAR-T) called C-CAR039 for adults with certain types of large B-cell lymphoma that has come back or did not respond to treatment. It may help by attaching to lymphoma cells and training your immune system to fight them.
BeijingAges 18 years+ - NCT05755087RecruitingPhase 1
Tegavivint for relapsed or hard-to-treat lymphoma patients
This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.
Columbus, OhioAges 18 years+ - NCT05757219RecruitingPhase 2
Itacitinib before CAR T for aggressive B-cell lymphoma
This trial tests itacitinib given before CAR T cell therapy to see if it can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). It may help by calming certain immune signals before CAR T is started.
Tampa, FloridaAges 18 years+ - NCT05773040RecruitingPhase 1
CAR T-cell therapy made from your own immune cells
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
Houston, TexasAges 18 years+ - NCT05685173RecruitingPhase 1
Study safety of REGN5837 with odronextamab in adult B-cell lymphoma
This Phase 1 trial tests whether a new medicine (REGN5837) given with odronextamab is safe in adults with aggressive B-cell non-Hodgkin lymphoma. It may help researchers learn if this combination can work for patients whose disease has progressed after earlier treatments.
Duarte, CaliforniaAges 18 years+ - NCT05702853RecruitingPhase 1/Phase 2
CAR T-cell therapy after CD34 selection for CD19 lymphoma or CLL
This Phase 1/2 study tests a customized type of immune cell treatment (CD19 CAR T-cells) for people with certain relapsed or hard-to-treat lymphomas or CLL/SLL. It aims to improve control of disease by targeting the CD19 marker on cancer cells.
Charleston, South CarolinaAges 18 years+ - NCT05674175RecruitingPhase 1/Phase 2
Test two engineered immune cell treatments for B-cell leukemia
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
Philadelphia, PennsylvaniaAges Up to 29 years - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Bullhead City, ArizonaAges 18 years+ - NCT05672251RecruitingPhase 2
Testing two antibody drugs for lymphoma that came back
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Duarte, CaliforniaAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Orange, CaliforniaAges 18 years+ - NCT05615636RecruitingPhase 2
Study of four medicines for relapsed B-cell lymphoma
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Houston, TexasAges 18 years+ - NCT05533775RecruitingPhase 1/Phase 2
Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Birmingham, AlabamaAges 6 months–30 years - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Gilbert, ArizonaAges 18 years+ - NCT05544968RecruitingPhase 1
CD30-targeted cell treatment for hard-to-treat blood cancers
This Phase 1 trial studies an experimental treatment that targets a marker called CD30 on cancer cells. It is for adults with certain relapsed or refractory CD30-positive blood cancers to see how well the treatment works and what side effects it causes.
Milwaukee, WisconsinAges 18 years+ - NCT05463263RecruitingPhase 1/Phase 2
Study drug for adults with relapsed or treatment-resistant lymphomas
This Phase 1/2 study tests dencatistat (STP938) to treat adults whose B-cell or T-cell lymphoma has come back or not responded to treatment. It looks at safety, the best dose, and whether it can shrink tumors or improve disease control when standard options have not helped.
Denver, ColoradoAges 18 years+ - NCT05464719RecruitingPhase 2
Loncastuximab for lymphoma patients in partial remission after CAR T
This trial studies loncastuximab tesirine (a targeted cancer medicine) given after CAR T-cell therapy when your lymphoma has improved to a partial remission. It aims to reduce the chance of the lymphoma returning after CAR T.
Houston, TexasAges 18 years+ - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39 - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05432635RecruitingPhase 1
CAR T-cell and vaccine treatment after stem cell transplant
This Phase 1 study tests a customized immune-cell treatment (CAR T-cells) plus a vaccine given after stem cell transplant for certain aggressive B-cell non-Hodgkin lymphomas. It aims to help your immune system better recognize and attack the lymphoma and to see how safe the approach is.
Duarte, CaliforniaAges 18 years+ - NCT05389423RecruitingPhase 1
Pomalidomide plus chemotherapy for HIV-related lymphoma
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
Bethesda, MarylandAges 18–120 - NCT05377307Recruiting
Long-term follow-up for gene-edited immune cell therapy
This study checks how people are doing years after receiving a specific company’s gene-edited immune cell treatment. It helps researchers learn about long-term safety and health outcomes.
Kaohsiung, TaiwanAges Any age - NCT05365659RecruitingPhase 1
Testing IKS03 for advanced B-cell lymphoma
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
Baltimore, MarylandAges 18 years+
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma, b-cell?
- Yes. Clin2 currently lists 534 recruiting lymphoma, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.